Proof-of-concept Multicentre, Prospective, Randomised, Open-label and Parallel Group Clinical Trial to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5 mg Six-monthly in Patients With Recurrence of Prostate Cancer Previously Treated With Radiotherapy.

Trial Profile

Proof-of-concept Multicentre, Prospective, Randomised, Open-label and Parallel Group Clinical Trial to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5 mg Six-monthly in Patients With Recurrence of Prostate Cancer Previously Treated With Radiotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Triptorelin (Primary)
  • Indications Prostate cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ANABRAQ
  • Sponsors Ipsen
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 02 Apr 2015 Status changed from active, no longer recruiting to discontinued, as reported by ClinicalTrials.gov.
    • 14 Nov 2014 New source identified and integrated: European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top